LONDON, April 14, 2016 /PRNewswire/ --
Norgine B.V. today presented new positive UK real world practice data from the IMPRESS retrospective observational study for rifaximin-α at the International Liver Congress 2016, 13-16 April in Barcelona, Spain. These data showed that in UK clinical practice, treatment with rifaximin-α for hepatic encephalopathy:
- is well tolerated
- is associated with reductions in hospitalisation frequency, bed occupancy (including critical care) and emergency room visits - within six months of treatment initiation and sustained at 12 months.
The IMPRESS retrospective observational study included 11 specialist National Health Service (NHS) centres and 145 patients prescribed rifaximin-α for hepatic encephalopathy between July 2008 and May 2014.
Peter Martin, COO at Norgine said; "These positive real life use results for rifaximin-α prove that this treatment is not only well tolerated but also reduces hospital resource. By using rifaximin-α healthcare systems can make substantial savings as it reduces hospitalisations and bed occupancy within six months of treatment. Hepatic encephalopathy has a huge impact on the lives of patients - as often they are not able to care for themselves, their families, careers and health systems overall and rifaximin-α can help reduce this burden."
Norgine currently holds marketing rights for XIFAXAN® 550mg (known as TARGAXAN®▼ 550 in the UK and some other markets) in Australia, Belgium, Denmark, Finland, Germany, Luxembourg, Netherlands, New Zealand, Norway, Republic of Ireland, Sweden, United Kingdom and Switzerland. Norgine and Alfa Wassermann co-promote the product under the TIXTAR® brand name in France.
The product is reimbursed in Australia, England, Germany, Ireland, Luxembourg, New Zealand, Norway, Scotland, Sweden, Switzerland and Wales.
To view the full press release go to http://www.norgine.com/media/press-releases
Isabelle Jouin, T: +44-(0)1895-453643
Charlotte Andrews, T: +44-(0)1895-453607
Follow us @norgine
SOURCE Norgine B.V.